View Post

Eli Lilly, Sermonix Pharma Partner on Phase II Trial of Drug Combo in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: Columbus, Ohio-based Sermonix Pharmaceuticals said on Wednesday that it is collaborating with Eli Lilly in an upcoming Phase II trial studying Sermonix’s lasofoxifene in combination with Lilly’s CDK 4 and 6 inhibitor abemaciclib (Verzenio) in estrogen receptor-positive, HER2-negative metastatic breast cancer patients who also harbor an ESR1 mutation. The trial, which is expected to start …